

II. Claims 14 and 15, drawn to a method of identifying a compound that interacts with the NEMO binding domain, comprising exposing cells which express NEMO and NF-kB to a test compound, classified in class 435, subclass 7.1, 7.95.

III. Claims 16-25 and 35 drawn to an anti-inflammatory compound comprising a NEMO binding domain fused with at least one membrane translocation domain, and a composition comprising the said fusion anti-inflammatory compound, wherein the NEMO binding domain comprises the amino acid sequence set forth in SEQ ID NO: 2-19, and fragments or variants thereof, classified in class 530, subclasses 827 and 845; class 514, subclass 2. Should Group II be elected, applicants are required to select one sequence of peptides of SEQ ID NOs: 2-19.

IV. Claim 26, drawn to an isolated nucleic acid molecule that encodes the amino acid sequence of SEQ ID NOs: 2-19, and fragments thereof, classified in class 536, subclass 23.5. Should Group IV be elected, applicants are required to select one sequence of peptides of SEQ ID NOs: 2-19.

Applicants hereby elect the Group I invention (claims 1-13 and 27-34) drawn to a method of modulating NF-kB induction in a cell by contacting a cell with an anti-inflammatory compound comprising at least one NEMO binding domain, wherein the said compound is capable of blocking the interaction between IKK and NEMO; a method of treating a subject suffering from inflammatory disorder comprising administering an anti-inflammatory compound. Applicants further elect the species of SEQ ID NO: 6, *without traverse*.

Applicants reserve the right to traverse the restriction between the non-elected groups in this or a separate application.


Finally, it is Applicants' understanding that, under 35 U.S.C. §121, an election of a single peptide for prosecution on the merits is required, to which the claims will be restricted if no generic claim is finally held allowable. Applicants submit that claims 1 and 27 are generic.

Applicants further understand that upon the allowance of a generic claim, Applicants will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 C.F.R. § 1.141.

**SUMMARY**

If a telephone conversation with Applicants' Attorney would expedite the prosecution of the above-identified application, the Examiner is urged to call Applicants' Attorney at (617) 227-7400.

Respectfully submitted,



Maria Laccotripe Zacharakis, Ph.D.

Attorney for Applicants

Limited Recognition Under 37 C.F.R. § 10.9(b)

LAHIVE & COCKFIELD, LLP  
28 State Street  
Boston, MA 02109  
Tel. (617) 227-7400  
Dated: **August 25, 2003**